-
Clene Inc NASDAQ:CLNN Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland.
Location: | Website: clene.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
42.12M
Cash
21.68M
Avg Qtr Burn
-6.843M
Short % of Float
3.32%
Insider Ownership
28.28%
Institutional Own.
13.11%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CNM-Au8 Details Multiple sclerosis | Phase 3 Initiation | |
CNM-Au8 Details Amyotrophic lateral sclerosis | Phase 3 Initiation | |
CNM-Au8 Details Amyotrophic lateral sclerosis | Phase 2 Update | |
CNM-Au8 Details Multiple sclerosis | Phase 2 Update | |
CNM-Au8 Details Parkinson's disease | Failed Discontinued | |
CNM-ZnAg Details COVID-19 | Failed Discontinued |